Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients

W. A. Anwar, Sherif Abdel-Rahman, R. A. El-Zein, H. M. Mostafa, W. W. Au

Research output: Contribution to journalArticle

132 Citations (Scopus)

Abstract

Polymorphic changes in the GSTM1, CYP2E1 and the CYP2D6 genes have been reported to be individually associated with increased susceptibility to certain cancers. In the present study, the relationship between genetic polymorphism for these genes and development of urinary bladder cancer among Egyptian patients was investigated. Our results indicate that the frequency of bladder cancer patients with the GSTM1 null genotype is significantly higher than that of the normal controls (86.3 and 47.6%, respectively) with an odds ratio (OR) of 6.97 (95% CL = 1.59-30.57, Fisher's exact P = 0.008). In contrast, our investigation failed to demonstrate any difference in the distribution of CYP2E1 polymorphism between bladder cancer patients and controls as detected by PstI restriction fragment length polymorphism (RFLP) analysis. RFLP analysis of the CYP2D6 gene revealed a non-significant increase in the number of extensive metabolizers (EM) among the patients compared to the controls (68 versus 48%). However, the EM genotypes enhances the risk further for individuals harboring the GSTM1 null genotype as individuals harboring both the EM and the GSTM1 null genotypes have an odds ratio of 14.0 (95% CL = 1.3 - 151.4, Fisher's exact P = 0.02) compared to individuals harboring the EM and the GSTM1+/+ genotypes. In conclusion, our results indicate that genetic polymorphism, especially in GSTM1 and CYP2D6 could play an important role as host risk factors for development of urinary bladder cancer among Egyptians.

Original languageEnglish (US)
Pages (from-to)1923-1929
Number of pages7
JournalCarcinogenesis
Volume17
Issue number9
StatePublished - Sep 1996

Fingerprint

Cytochrome P-450 CYP2E1
Cytochrome P-450 CYP2D6
Genetic Polymorphisms
Urinary Bladder Neoplasms
Genotype
Restriction Fragment Length Polymorphisms
Odds Ratio
Genes
Neoplasms

ASJC Scopus subject areas

  • Cancer Research

Cite this

Anwar, W. A., Abdel-Rahman, S., El-Zein, R. A., Mostafa, H. M., & Au, W. W. (1996). Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients. Carcinogenesis, 17(9), 1923-1929.

Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients. / Anwar, W. A.; Abdel-Rahman, Sherif; El-Zein, R. A.; Mostafa, H. M.; Au, W. W.

In: Carcinogenesis, Vol. 17, No. 9, 09.1996, p. 1923-1929.

Research output: Contribution to journalArticle

Anwar, WA, Abdel-Rahman, S, El-Zein, RA, Mostafa, HM & Au, WW 1996, 'Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients', Carcinogenesis, vol. 17, no. 9, pp. 1923-1929.
Anwar, W. A. ; Abdel-Rahman, Sherif ; El-Zein, R. A. ; Mostafa, H. M. ; Au, W. W. / Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients. In: Carcinogenesis. 1996 ; Vol. 17, No. 9. pp. 1923-1929.
@article{c72c5cfe0fff45c0bfef7ff6b5bc8255,
title = "Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients",
abstract = "Polymorphic changes in the GSTM1, CYP2E1 and the CYP2D6 genes have been reported to be individually associated with increased susceptibility to certain cancers. In the present study, the relationship between genetic polymorphism for these genes and development of urinary bladder cancer among Egyptian patients was investigated. Our results indicate that the frequency of bladder cancer patients with the GSTM1 null genotype is significantly higher than that of the normal controls (86.3 and 47.6{\%}, respectively) with an odds ratio (OR) of 6.97 (95{\%} CL = 1.59-30.57, Fisher's exact P = 0.008). In contrast, our investigation failed to demonstrate any difference in the distribution of CYP2E1 polymorphism between bladder cancer patients and controls as detected by PstI restriction fragment length polymorphism (RFLP) analysis. RFLP analysis of the CYP2D6 gene revealed a non-significant increase in the number of extensive metabolizers (EM) among the patients compared to the controls (68 versus 48{\%}). However, the EM genotypes enhances the risk further for individuals harboring the GSTM1 null genotype as individuals harboring both the EM and the GSTM1 null genotypes have an odds ratio of 14.0 (95{\%} CL = 1.3 - 151.4, Fisher's exact P = 0.02) compared to individuals harboring the EM and the GSTM1+/+ genotypes. In conclusion, our results indicate that genetic polymorphism, especially in GSTM1 and CYP2D6 could play an important role as host risk factors for development of urinary bladder cancer among Egyptians.",
author = "Anwar, {W. A.} and Sherif Abdel-Rahman and El-Zein, {R. A.} and Mostafa, {H. M.} and Au, {W. W.}",
year = "1996",
month = "9",
language = "English (US)",
volume = "17",
pages = "1923--1929",
journal = "Carcinogenesis",
issn = "0143-3334",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients

AU - Anwar, W. A.

AU - Abdel-Rahman, Sherif

AU - El-Zein, R. A.

AU - Mostafa, H. M.

AU - Au, W. W.

PY - 1996/9

Y1 - 1996/9

N2 - Polymorphic changes in the GSTM1, CYP2E1 and the CYP2D6 genes have been reported to be individually associated with increased susceptibility to certain cancers. In the present study, the relationship between genetic polymorphism for these genes and development of urinary bladder cancer among Egyptian patients was investigated. Our results indicate that the frequency of bladder cancer patients with the GSTM1 null genotype is significantly higher than that of the normal controls (86.3 and 47.6%, respectively) with an odds ratio (OR) of 6.97 (95% CL = 1.59-30.57, Fisher's exact P = 0.008). In contrast, our investigation failed to demonstrate any difference in the distribution of CYP2E1 polymorphism between bladder cancer patients and controls as detected by PstI restriction fragment length polymorphism (RFLP) analysis. RFLP analysis of the CYP2D6 gene revealed a non-significant increase in the number of extensive metabolizers (EM) among the patients compared to the controls (68 versus 48%). However, the EM genotypes enhances the risk further for individuals harboring the GSTM1 null genotype as individuals harboring both the EM and the GSTM1 null genotypes have an odds ratio of 14.0 (95% CL = 1.3 - 151.4, Fisher's exact P = 0.02) compared to individuals harboring the EM and the GSTM1+/+ genotypes. In conclusion, our results indicate that genetic polymorphism, especially in GSTM1 and CYP2D6 could play an important role as host risk factors for development of urinary bladder cancer among Egyptians.

AB - Polymorphic changes in the GSTM1, CYP2E1 and the CYP2D6 genes have been reported to be individually associated with increased susceptibility to certain cancers. In the present study, the relationship between genetic polymorphism for these genes and development of urinary bladder cancer among Egyptian patients was investigated. Our results indicate that the frequency of bladder cancer patients with the GSTM1 null genotype is significantly higher than that of the normal controls (86.3 and 47.6%, respectively) with an odds ratio (OR) of 6.97 (95% CL = 1.59-30.57, Fisher's exact P = 0.008). In contrast, our investigation failed to demonstrate any difference in the distribution of CYP2E1 polymorphism between bladder cancer patients and controls as detected by PstI restriction fragment length polymorphism (RFLP) analysis. RFLP analysis of the CYP2D6 gene revealed a non-significant increase in the number of extensive metabolizers (EM) among the patients compared to the controls (68 versus 48%). However, the EM genotypes enhances the risk further for individuals harboring the GSTM1 null genotype as individuals harboring both the EM and the GSTM1 null genotypes have an odds ratio of 14.0 (95% CL = 1.3 - 151.4, Fisher's exact P = 0.02) compared to individuals harboring the EM and the GSTM1+/+ genotypes. In conclusion, our results indicate that genetic polymorphism, especially in GSTM1 and CYP2D6 could play an important role as host risk factors for development of urinary bladder cancer among Egyptians.

UR - http://www.scopus.com/inward/record.url?scp=0029833473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029833473&partnerID=8YFLogxK

M3 - Article

C2 - 8824515

AN - SCOPUS:0029833473

VL - 17

SP - 1923

EP - 1929

JO - Carcinogenesis

JF - Carcinogenesis

SN - 0143-3334

IS - 9

ER -